945PA phase I/II study of chemo-immunotherapy with durvalumab (durva) and pegylated liposomal doxorubicin (PLD) in platinum-resistant recurrent ovarian cancer (PROC). (23rd October 2018) - O'Cearbhaill, R E; Wolfer, A; Disilvestro, P; O'Malley, D M; Sabbatini, P; Shohara, L; Schwarzenberger, P O; Ricciardi, T; Macri, M; Ryan, A; Venhaus, R R; Bryan, J K; et al.